Long‐COVID symptoms improved after MDMA and psilocybin therapy: A case report
Harman Chopra, Tim Furnish, Monica Verduzco-Gutierrez, David S Jevotovsky, Joel Castellanos
Clinical Case Reports May 28, 2024 DOI: 10.1002/ccr3.8791 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | 41-year-old fully vaccinated female with Long-COVID syndrome |
| Interventions | Psilocybin MDMA |
| Topics | MDMA Psilocybin Psychedelic-assisted therapy |
| Keywords | Long-covid Covid‐19 Case report Long‐covid Neurotropics Covid-19 recovery Case studies Neurological treatment |
| Citations | 6 |
| Key findings | A patient with Long-COVID syndrome obtained significant symptomatic relief after self-medicating with psilocybin and MDMA. |
Abstract
Key Clinical Message Long‐COVID syndrome lacks effective holistic treatment options. We present a case of a 41‐year‐old fully vaccinated female with Long‐COVID syndrome who obtained significant symptomatic relief after self‐medicating with psilocybin and MDMA. Abstract Long‐COVID, a syndrome persisting after the acute phase of coronavirus disease 2019 (COVID‐19), lacks effective holistic treatment options. We present a case of a 41‐year‐old fully vaccinated female with Long‐COVID syndrome who obtained significant symptomatic relief by self‐prescribing psilocybin and MDMA. Future research is needed to assess safety and efficacy.
Comparable studies
Other case reports and case series on MDMA and psychedelic-assisted therapy, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Treatment of neuropathic pain with repeated low-dose MDMA: a case report. 64-year-old male with neuropathic pain after chemotherapy and traumatic life experiences | 2025 | Case study | n = 1 |
| New‐Onset Obsessive–Compulsive Symptoms After MDMA‐Assisted Psychotherapy in a Patient With Refractory PTSD: A Case Report 31-year-old woman with chronic PTSD, nondistressing childhood compulsions, and complex... | 2026 | Case study | n = 1 |
Citations in the library
Cited by 5
- The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies Progress in Neuro-Psychopharmacology and Biological Psychiatry September 7, 2024
- Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives Advanced Science March 20, 2025
- Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation Journal of Psychoactive Drugs March 14, 2025
- Psychedelics in functional disorders: A scoping review Progress in Neuro-Psychopharmacology and Biological Psychiatry February 10, 2026
- Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry March 20, 2025
Cites 9
- Default Mode Network Modulation by Psychedelics: A Systematic Review The International Journal of Neuropsychopharmacology October 21, 2022
- Psychedelic Drug Legislative Reform and Legalization in the US JAMA Psychiatry December 7, 2022
- Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2021
- Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review Psychopharmacology March 7, 2022
- Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial Headache: The Journal of Head and Face Pain November 1, 2022
and 4 more in the library